Crucell’s second 2010 quarter revenues set a record

Tuesday 17 August 2010

Total revenues and other operating income of Crucell NV rose by 63% to a record €128.6 million in the second 2010 quarter, mainly due to booming sales of Quinvaxem in the developing world.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Netherlands